North China Pharmaceutical Company.Ltd (SHA:600812)
China flag China · Delayed Price · Currency is CNY
4.830
-0.130 (-2.62%)
May 20, 2026, 11:29 AM CST

SHA:600812 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8,7179,1389,79810,07010,44910,304
Other Revenue
103.99103.9971.7650.3251.1980.2
8,8219,2429,87010,12010,50010,385
Revenue Growth (YoY)
-10.78%-6.36%-2.48%-3.62%1.11%-9.64%
Cost of Revenue
6,0776,3636,7326,9077,0636,691
Gross Profit
2,7442,8783,1383,2133,4373,694
Selling, General & Admin
1,6781,7802,0102,2682,4242,796
Research & Development
354.42339.77336.15294.2215.17151.93
Other Operating Expenses
93.787.4190.82104.23117.57123.33
Operating Expenses
2,1662,2512,4792,6772,8023,094
Operating Income
577.45627.16658.87536.44634.8600.11
Interest Expense
-339.14-361.55-458.7-501.9-599.39-642.69
Interest & Investment Income
91.5586.4471.4274.5284.17126.62
Currency Exchange Gain (Loss)
-4.96-4.9617.5711.4923.31-8.32
Other Non Operating Income (Expenses)
-17.83-5.298.92-11.35-748.96-13.91
EBT Excluding Unusual Items
307.07341.81298.08109.2-606.0761.82
Impairment of Goodwill
---3.34---
Gain (Loss) on Sale of Assets
0.840.830.440.760.213.4
Asset Writedown
-7.64-0.76-1.4-0.05--
Legal Settlements
-1.72-1.72-0.5-0.49-0.78-1.14
Other Unusual Items
21.9817.2516.5549.1241.5670.84
Pretax Income
320.54357.41309.83158.54-565.07134.91
Income Tax Expense
90.3399.9694.87109.15113.7199.52
Earnings From Continuing Operations
230.2257.45214.9749.39-678.7835.38
Minority Interest in Earnings
-69.17-74.4-87.97-44.5-10.45-16.65
Net Income
161.04183.06126.994.89-689.2318.73
Net Income to Common
161.04183.06126.994.89-689.2318.73
Net Income Growth
-3.18%44.15%2496.79%---80.76%
Shares Outstanding (Basic)
1,7101,7111,7161,6301,7151,702
Shares Outstanding (Diluted)
1,7101,7111,7161,6301,7151,702
Shares Change (YoY)
-0.92%-0.31%5.27%-4.92%0.70%4.96%
EPS (Basic)
0.090.110.070.00-0.400.01
EPS (Diluted)
0.090.110.070.00-0.400.01
EPS Growth
-2.28%44.59%2366.67%---81.67%
Free Cash Flow
627.68634.53445.35401.23454.81502.75
Free Cash Flow Per Share
0.370.370.260.250.270.29
Dividend Per Share
0.0350.0350.0300.010-0.060
Dividend Growth
16.67%16.67%200.00%--100.00%
Gross Margin
31.11%31.15%31.79%31.75%32.73%35.57%
Operating Margin
6.55%6.79%6.68%5.30%6.05%5.78%
Profit Margin
1.83%1.98%1.29%0.05%-6.56%0.18%
Free Cash Flow Margin
7.12%6.87%4.51%3.96%4.33%4.84%
EBITDA
1,4911,5171,4521,2751,3471,224
EBITDA Margin
16.90%16.41%14.71%12.60%12.83%11.79%
D&A For EBITDA
913.47889.37792.99739.01712624
EBIT
577.45627.16658.87536.44634.8600.11
EBIT Margin
6.55%6.79%6.68%5.30%6.05%5.78%
Effective Tax Rate
28.18%27.97%30.62%68.85%-73.77%
Revenue as Reported
8,8219,2429,87010,12010,50010,385
Advertising Expenses
-109.62119.86133.01127.89185.19
Source: S&P Global Market Intelligence. Standard template. Financial Sources.